• Evonik raised FY 2026 adjusted EBITDA guidance to EUR 2-2.2 billion from EUR 1.7-2 billion.
• New sales view around EUR 15 billion, up from EUR 13.5-14.5 billion; 2025 sales EUR 14.1 billion.
• Q2 adjusted EBITDA EUR 630 million, up 24% year on year; strength led by Advanced Technologies, up 25%.
• Free cash flow target unchanged at about 40% conversion; Q2 free cash flow EUR 49 million versus EUR -211 million.
• Capex expected around EUR 750 million; ROCE seen slightly above 2025’s 6.1%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evonik Industries AG published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.